<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03788538</url>
  </required_header>
  <id_info>
    <org_study_id>20181224</org_study_id>
    <nct_id>NCT03788538</nct_id>
  </id_info>
  <brief_title>Effects of Dexmedetomidine on Modulation of Perioperative Blood Glucose</brief_title>
  <official_title>Effects of Dexmedetomidine on Modulation of Perioperative Blood Glucose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhuan Zhang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yangzhou University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aimed to explore effects of dexmedetomidine on modulation of perioperative
      blood glucose and relevant hormone during the general anesthesia with surgery time ≥ 4 hours,
      and the effects on postoperative complications. Eighty participants (American Society of
      Anesthesiologists grades I or II, of both sexes,aged 18-65 yr,with BMI of 18.5-27 kg/m2)
      scheduled for elective surgery under general anesthesia with surgery time ≥ 4 hours were
      enrolled in this study. The participants were divided into four groups: control group (group
      C)，0.25 μg/kg/h group (group 1), 0.5 μg/kg/h group (group 2), 1 μg/kg/h group (group 3).10
      minutes before anesthesia induction, all participants were administrated with dexmedetomidine
      1 μg/kg/min.At the beginning of induction, dexmedetomidine was changed to corresponding
      maintenance dose in each group. Blood samples were taken at the beginning of dexmedetomidine
      (T0), the beginning of skin incision (T1), 1 h after skin incision (T2), 2 h after skin
      incision (T3), the end of the surgery (T4) and 24 h after operation (T5) for the value of
      blood glucose and relevant hormone. Also, investigators also record the total amount of
      propofol and sufentanil at the end of surgery,and the complications within 24 h after the
      surgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Anticipated">July 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effects of dexmedetomidine on perioperative blood glucose</measure>
    <time_frame>Intraoperative</time_frame>
    <description>The changes of blood glucose during the surgery period</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Dexmedetomidine</condition>
  <condition>Blood Glucose</condition>
  <arm_group>
    <arm_group_label>group 1 with no dexmedetomidine</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>group 2 with dexmedetomidine 0.25μg/kg/h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>group 2 with dexmedetomidine 0.5μg/kg/h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>group 3 with dexmedetomidine 1μg/kg/h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexmedetomidine</intervention_name>
    <description>10 minutes before anesthesia induction, all patients were administrated with dexmedetomidine 1 μg/kg/min.At the beginning of induction, dexmedetomidine was changed to corresponding maintenance dose in each group.</description>
    <arm_group_label>group 2 with dexmedetomidine 0.25μg/kg/h</arm_group_label>
    <arm_group_label>group 2 with dexmedetomidine 0.5μg/kg/h</arm_group_label>
    <arm_group_label>group 3 with dexmedetomidine 1μg/kg/h</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients undergoing operations over 4 h under general anesthesia

        Exclusion Criteria:

          -  the patients with bradycardia, hypoglycemia, heart disease, adrenal tumor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>zhang zhuan, MD</last_name>
    <phone>+86 15062791355</phone>
    <email>zhangzhuancg@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>the Affiliated Hospital of Yangzhou University, Yangzhou University</name>
      <address>
        <city>Yangzhou</city>
        <state>Jiangsu</state>
        <zip>225012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xinnong Liu, Dr.</last_name>
      <phone>+8615062791355</phone>
      <email>zhangzhuanjy@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>December 25, 2018</study_first_submitted>
  <study_first_submitted_qc>December 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 27, 2018</study_first_posted>
  <last_update_submitted>December 27, 2018</last_update_submitted>
  <last_update_submitted_qc>December 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Yangzhou University</investigator_affiliation>
    <investigator_full_name>Zhuan Zhang</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

